Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419445 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
A Phase 1 study, sponsored by CoMentis.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00419445: Completed Phase 1 study, sponsored by CoMentis.
NCT00419445 is a Phase 1 study that has completed, run by CoMentis. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419445, a Phase 1 study, has completed, sponsored by CoMentis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.
Interventions
- DRUG GTS21/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419445
The ClinicalTrials.gov registry entry for NCT00419445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CoMentis, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GTS21/Placebo is the first listed.
NCT00419445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419445 about?
NCT00419445 is a clinical study titled "Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder". This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.
What is the current status of trial NCT00419445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2007-02. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00419445?
The interventions under investigation include: GTS21/Placebo (DRUG).
Who is sponsoring clinical trial NCT00419445?
This trial is sponsored by CoMentis, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.